Clinical Trial Results: A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation [Phase 2]

View source ↗

Summary

Phase 2 trial results for XPro1595 in early Alzheimer's disease with inflammatory biomarkers have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia
• Neurocognitive Disorders
• Neurodegenerative Diseases
• Tauopathies

Drugs mentioned

• XPro1595 (XPro1595)

Snippet

Sponsor: Inmune Bio, Inc. | Conditions: Alzheimer Disease, Dementia | Phase 2 | Status: COMPLETED | Results posted: 2026-06-29